Almost Complete Response with a Single Administration 225Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary

Nalan Alan Selçuk; Emre Demirci; Meltem Ocak; Türkay Toklu; Selçuk Ergen; Levent Kabasakal

doi:10.4274/mirt.galenos.2022.64497

Almost Complete Response with a Single Administration ²²⁵Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary

PDF

Interesting Image

Almost Complete Response with a Single Administration ²²⁵Ac-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary

Mol Imaging Radionucl Ther 2022;31(2):139-141 DOI: 10.4274/mirt.galenos.2022.64497

, , , , ,

PDF

Permissions

Abstract

Neuroendocrine tumors (NETs) are being seen increasingly frequently, and the only known curative treatment method is surgical resection. Peptide receptor radionuclide therapy (PRRT) is a treatment option that the most contributes to progression-free survival and overall survival in metastatic cases.β-emitting radionuclides are traditionally used for PRRT. Nowadays, alpha particle-emitting radionuclides are being developed, with advantages in terms of very high energy and a short path length, which should theoretically show higher efficacy. In this case; in a patient with NET diagnosis who had multiple (>50) lesions in the abdomen, almost all the lesions disappeared with a single dose application. This paper aims to present a case in which we observed the efficacy of ²²⁵Ac-DOTATATE treatment, which is an alpha treatment.

Keywords: 225Ac targeted alpha therapy, neuroendocrine tumors, peptide receptor radionuclide therapy

References

1

Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, Lepensky C, Kwekkeboom DJ, Baum RP, Krenning EP, Modlin IM. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging 2015;42:5-19.

2

Navalkissoor S, Grossman A. Targeted alpha particle therapy for neuroendocrine tumours: the next generation of peptide receptor radionuclide therapy. Neuroendocrinology 2019;108:256-264.

3

Nayak TK, Norenberg JP, Anderson TL, Prossnitz ER, Stabin MG, Atcher RW. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells. Nucl Med Biol 2007;34:185-193.

4

Ocak M, Toklu T, Demirci E, Selçuk N, Kabasakal L. Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor. Eur J Nucl Med Mol Imaging 2020;47:2711-2712.

5

Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging 2020;47:934-946.